ArticleFrontiers in endocrinology2026
Optimizing mature oocyte yield in IVF: clinical comparison of r-hFSH+r-hLH and HMG in women with a stimulation dosage of at least 300 IU of gonadotropins.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of adding r-LH to r-FSH during ovarian stimulation on reproductive outcomes of women with polyendocrine metabolic ovarian syndrome undergoingFrontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To study the impact of luteinizing hormone (LH) in stimulation medication on the mature oocyte yield obtained in in women receiving ovarian stimulation (OS) with a dosage of at least 300 IU gonadotropins. Design: Retrospective cohort study (01/2016-05/2024). Setting: Tertiary assisted reproductive technology center. Patients: Women undergoing OS stimulation of at least 300 IU gonadotropins. Intervention: OS using r-hFSH+r-hLH or HMG as stimulation medication. Main outcome measure: Retrieved mature oocyte number. Results: A total of 1,286 patients (696 in the HMG group and 590 in the r-hFSH+r-hLH group) were included in the unmatched cohort. Before matching, the r-hFSH+r-hLH versus HMG-groups showed significant differences in AMH (0.8 vs 1.2ng/mL,p<0.001), starting doses (85.1% vs 70.1% on 450IU,p<0.001), and categorized BMI distribution (p=0.003). After propensity score matching (age, BMI, AMH, basal FSH, starting dose), 1052 cycles were analyzed with a 1:1 match ratio. In the matched cohort after further adjusting for confounders, r-hFSH+r-hLH use was associated with significantly higher collected oocyte count (IRR 1.10, 95% CI 1.03-1.17, p=0.004) and mature oocyte count (IRR 1.12, 95% CI 1.04-1.21, p=0.003) compared to HMG. The sensitivity analysis looking at the interaction of AMH with gonadotropin type showed the effect is mostly significant for those with normal ovarian reserve (AMH between 1.0-3.5ng/mL, IRR: 1.19, 95% CI: 1.07 to 1.33, P = 0.001) but not for those with low (≤1ng/mL, P = 0.180) or high ovarian reserve (>3.5ng/mL, P = 0.932). Analysis of maturation rates showed no significant effect of medication type (p=0.143). The euploid blastocyst count after stimulation in the matched cohort and HMG use was associated with a 22% lower yield compared to r-hFSH+r-hLH (IRR 0.78, 95% CI 0.66-0.93, p=0.006) after adjusting for AMH, basal FSH, female age, dose, body mass index. Conclusion: The use of r-hFSH+r-hLH is associated with a significantly higher mature oocyte and euploid blastocyst count compared to HMG and the effect was most pronounced in women with normal ovarian reserve.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.